

Seeks long-term capital appreciation.

Tickers A: HGHAX C: HGHGX F: HGHFX I: HGHIX R3: HGHRX
R4: HGHSX R5: HGHTX R6: HGHVX Y: HGHYX

Inception Date 05/01/2000

Morningstar® Category Health

Lipper Peer Group Global Health/Biotechnology

Overall Morningstar Rating™ (I-Share)*



133 Products | Health Category Based on Risk-Adjusted Returns as of 9/30/20


Performance (%)

Class	QTD	YTD	Average Annual Total Returns				SI
			1 Year	3 Year	5 Year	10 Year	
A	6.06	11.04	32.64	12.22	12.11	16.46	11.91
A with 5.5% Max Sales Charge	—	—	25.35	10.12	10.85	15.80	11.60
F	6.13	11.34	33.11	12.65	12.50	16.83	12.17
I	6.12	11.27	33.03	12.54	12.43	16.80	12.15
Y	6.12	11.30	33.04	12.61	12.53	16.93	12.43
S&P Composite 1500 Health Care Index	5.83	5.17	20.12	11.29	12.15	15.68	—
Morningstar Category	4.95	11.22	31.92	11.33	10.93	15.44	—
Lipper Peer Group	4.87	9.70	28.86	10.74	9.33	14.38	—

Share Class Inception: A, Y - 5/1/00; F - 2/28/17; I - 8/31/06. Performance shown prior to the inception of a class reflects performance and operating expenses of another class(es) (excluding sales charges, if applicable). Had fees and expenses of a class been reflected for the periods prior to the inception of that class, performance would be different. Since inception (SI) performance is from 5/1/00. Performance and expenses for other share classes will vary. Additional information is in the prospectus. Only Class A assesses a sales charge.

S&P Composite 1500 Health Care Index comprises those companies included in the S&P Composite 1500 that are classified as members of the GICS health care sector. Indices are unmanaged and not available for direct investment.

Value of a \$10,000 Investment (Class I)



Calendar Year Returns (%)

2019	33.69
2018	-2.74
2017	21.94
2016	-8.33
2015	12.97
2014	26.80
2013	49.95
2012	20.14
2011	8.03
2010	6.69

Portfolio Managers from Wellington Management

Jean M. Hynes, CFA
Senior Managing Director
Global Industry Analyst
Professional Experience Since 1991

Ann C. Gallo
Senior Managing Director
Global Industry Analyst
Professional Experience Since 1987

Robert L. Deresiewicz
Senior Managing Director
Global Industry Analyst
Professional Experience Since 1983

Rebecca Sykes, CFA
Senior Managing Director
Global Industry Analyst
Professional Experience Since 2005

The portfolio managers are supported by the full resources of Wellington.

Expenses (%)¹

	A	F	I	Y
Gross	1.31	0.92	1.02	1.03
Net	1.31	0.92	1.02	0.97

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. For more current performance information to the most recent month ended, please visit hartfordfunds.com.

Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in a fund's full prospectus and summary prospectus, which can be obtained by visiting hartfordfunds.com. Please read it carefully before investing.

¹ Expenses as shown in the Fund's most recent prospectus. Gross expenses do not reflect contractual fee waivers or expense reimbursement arrangements. Net expenses reflect such arrangements only with respect to Class Y. These arrangements remain in effect until 2/28/21 unless the Fund's Board of Directors approves an earlier termination.

Mutual funds are distributed by Hartford Funds Distributors, LLC (HFD), Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC (HFMC). Certain funds are sub-advised by Wellington Management Company LLP. HFD and HFMC are not affiliated with any sub-adviser.

Hartford Healthcare Fund

Sector Exposure (%)

	Fund		Benchmark	Underweight/Overweight	
	6/30/20	9/30/20	9/30/20	9/30/20	
Biopharma Mid Cap	14	11	1	10	
Biopharma Small Cap	10	10	0	10	
Health Care Services	22	21	21	0	
Medical Technology	28	33	36	-3	
Biopharma Large Cap	26	25	41	-16	

Based on sub-adviser's classification of health care subsectors, which includes combining biotechnology and pharmaceuticals in terms of capitalization: biopharma small-cap, biopharma mid-cap, and biopharma large-cap. Excludes cash. May not total to 100% due to rounding.

Top Ten Holdings (%)

as of 6/30/20

UnitedHealth Group, Inc.	7.63
Pfizer, Inc.	5.42
Eli Lilly & Co.	4.09
Thermo Fisher Scientific, Inc.	3.71
Bristol-Myers Squibb Co.	3.69
Danaher Corp.	3.11
Abbott Laboratories	2.95
AstraZeneca plc	2.69
Boston Scientific Corp.	2.46
Edwards Lifesciences Corp.	2.32
Percentage Of Portfolio	38.07

Top Ten Holdings (%)

as of 9/30/20

UnitedHealth Group, Inc.	7.79
Pfizer, Inc.	5.87
Thermo Fisher Scientific, Inc.	4.38
Danaher Corp.	3.66
Bristol-Myers Squibb Co.	3.65
Abbott Laboratories	3.58
Eli Lilly and Co.	3.56
Boston Scientific Corp.	2.99
AstraZeneca plc	2.70
Edwards Lifesciences Corp.	2.59
Percentage Of Portfolio	40.77

Net Assets	\$1.5 billion
# of Holdings	114
% in Equities	97%
% in Foreign Equities	17%
Beta (3 yrs)	1.06
R Squared (3 yrs)	0.87
Standard Deviation (3 yrs)	18.14%
Turnover	47%

Holdings Characteristics

	Fund	Benchmark
Price/Earnings	37.2x	15.6x
Price/Book	5.1x	4.8x
EPS Growth Rate	10.0%	9.0%
Return on Equity	5.1%	22.9%
Asset Weighted Market Cap (billions)	\$87.6	\$141.6
Median Market Cap (billions)	\$4.9	\$4.1

Market Cap Distribution (%)

Less than \$2 billion	10
\$2 billion - \$5 billion	8
\$5 billion - \$10 billion	9
Greater than \$10 billion	72
Not Classified	0

Benchmark S&P Composite 1500 Health Care Index

Holdings and characteristics are subject to change. Percentages may be rounded.

Important Risks: Investing involves risk, including the possible loss of principal. Security prices fluctuate in value depending on general market and economic conditions and the prospects of individual companies. • Risks of focusing investments on the healthcare related sector include regulatory and legal developments, patent considerations, intense competitive pressures, rapid technological changes, potential product obsolescence, and liquidity risk. • Small- and mid-cap securities can have greater risks and volatility than large-cap securities. • Foreign investments may be more volatile and less liquid than U.S. investments and are subject to the risk of currency fluctuations and adverse political and economic developments. These risks may be greater for investments in emerging markets.

Asset Weighted Market Cap is the value of a corporation as determined by the number of outstanding shares of common stock multiplied by the price per share. **Beta** measures the volatility of a portfolio relative to a benchmark. A beta of less than 1.00 indicates lower risk than the market; a beta of greater than 1.00 indicates higher risk than the market. **EPS Growth Rate** is the projected growth rate in earnings per share for the next five years. **Price/Book** is the ratio of a stock's price to its book value per share. **Price/Earnings** is the ratio of a stock's price to its earnings per share. **Return on Equity** is the average amount of net income returned as a percentage of shareholder's equity over the past five years. **R Squared** represents the percentage of the portfolio's movement that can be explained by the market. **Standard Deviation** measures the portfolio's total-return volatility. A higher standard deviation indicates greater historical volatility. **Turnover** is a percentage of a portfolio's assets that have changed over the course of a year. It is calculated by dividing the average assets during the period by the lesser of the value of purchases or the value of sales during the same period.

MF700_1020 219715

*Class I-Shares Star Ratings: 3-year 4 stars out of 133 products, 5-year 4 stars out of 124 products, and 10-year 4 stars out of 103 products for the period ended herein. Other share classes may have different ratings. The Morningstar Rating™ for funds, or "star rating", is calculated for funds and separate accounts with at least a 3-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. Star rating based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance (without adjusting for any sales load, if applicable), placing more emphasis on downward variations and rewarding consistent performance. 5 stars are assigned to the top 10%, 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5%, and 1 star to the bottom 10%. Overall Morningstar Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about the Morningstar Fund Ratings, including their methodology, please go to global.morningstar.com/managerdisclosures. ©2020 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.